Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma

Minaei, Soraya Emamgholizadeh; Khoei, Samideh; Khoee, Sepideh; Karimi, Mohammad Reza

doi:10.1016/j.biocel.2019.01.010

Cited by 42 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study used folic acid to functionalize TMZ-loaded poly(ethylene glycol)-poly(butylene-adipate)-poly(ethylene glycol)-coated magnetite NPs. This nanoformulation was tested in cancer C6 cell line showing higher cytotoxic effects compared to free TMZ and non-functionalized NPs, due to the addition of folic acid which increases the drug concentration inside cells [ 180 ].…”

Section: Advances In the Use Of Tmzmentioning

confidence: 99%

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Ortíz

Perazzoli

Cabeza

et al. 2021

View full text Add to dashboard Cite

: Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6- guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas. The main advantages are its high oral bioavailability (almost 100% although the concentration found in the cerebrospinal fluid was approximately 20% of the plasma concentration of TMZ), its lipophilic properties, and small size that confer the ability to cross the blood-brain barrier. Furthermore, this agent has demonstrated activity not only in brain tumors but also in a variety of solid tumors. However, conventional therapy using surgery, radiation, and TMZ in glioblastoma results in a median patient survival of 14.6 months. Treatment failure has been associated with the tumor drug resistance. This phenomenon has been linked to the expression of O6-methylguanine-DNA methyltransferase, but the mismatch repair system and the presence of cancer stem-like cells in tumors have also been related to TMZ resistance. The understanding of these mechanisms is essential for the development of new therapeutic strategies in the clinical use of TMZ, including the use of nanomaterial delivery systems and the association with other chemotherapy agents. The aim of this review is to summarize the resistance mechanisms of TMZ and the current advances to improve its clinical use.

show abstract

Section: Advances In the Use Of Tmzmentioning

confidence: 99%

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Ortíz

Perazzoli

Cabeza

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Due to the high toxicity of this drug, poor TMZ penetration across BBB, short halflife, the non-specific nature of the active substance and its non-targeted character, it is be better to functionalize it with different ligands (i.e., folic acid) and then load it in magnetite nanoparticles coated with a polymeric shell, composed of poly(ethylene glygol)poly(butylene adipate)-poly(ethylene glycol) (TMZ-SPION-PEG-PBA-PEG) [107]. This shell, formed from tree layers of biodegradable and biocompatible polymers, helps to improve the therapeutic efficacity.…”

Section: Chemotherapymentioning

confidence: 99%

“…The magnetic nanoparticles have dimensions between 10 and 100 nm, and thus the accumulation of SPIONs at the tumor zone is performed via the passive targeting process, as well as the EPR effect. Folic acid (FA) can be linked to the folate receptor (FR), which is present in cancerous cells such as GBM, breast ovarian unhealthy tissues [107].…”

Section: Chemotherapymentioning

confidence: 99%

Magnetic Nanoparticles Used in Oncology

et al. 2021

View full text Add to dashboard Cite

Recently, magnetic nanoparticles (MNPs) have more and more often been used in experimental studies on cancer treatments, which have become one of the biggest challenges in medical research. The main goal of this research is to treat and to cure advanced or metastatic cancer with minimal side effects through nanotechnology. Drug delivery approaches take into account the fact that MNPs can be bonded to chemotherapeutical drugs, nucleic acids, synthetized antibodies or radionuclide substances. MNPs can be guided, and different treatment therapies can be applied, under the influence of an external magnetic field. This paper reviews the main MNPs’ synthesis methods, functionalization with different materials and highlight the applications in cancer therapy. In this review, we describe cancer cell monitorization based on different types of magnetic nanoparticles, chemotherapy, immunotherapy, magnetic hyperthermia, gene therapy and ferroptosis. Examples of applied treatments on murine models or humans are analyzed, and glioblastoma cancer therapy is detailed in the review. MNPs have an important contribution to diagnostics, investigation, and therapy in the so called theranostics domain. The main conclusion of this paper is that MNPs are very useful in different cancer therapies, with limited side effects, and they can increase the life expectancy of patients with cancer drug resistance.

show abstract

“…The TMZ encapsulated in polymeric FA- functionalized nanoparticles, as evidenced by different assays with the C6 cell line, shown increased cytotoxicity, decreased anti-proliferative activity of tumor cells, increased levels of apoptosis and necrosis compared to free TMZ. The nanoparticles without TMZ showed no damage to the tested strains [ 86 ].…”

Section: Polymeric Nanosystemsmentioning

confidence: 99%

Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art

Filippo

Duarte

Luiz

et al. 2021

View full text Add to dashboard Cite

: Glioblastoma multiforme (GBM) is the most common primary malignant Central Nervous System cancer, responsible for about 4% of all deaths associated with neoplasia, characterized as one of the most fatal human cancers. Tumor resection does not possess curative character, thereby radio and/or chemotherapy are often necessary for the treatment of GBM. However, drugs used in GBM chemotherapy present some limitations, such as side effects associated with nonspecific drug biodistribution as well as limited bioavailability, which limits their clinical use. To attenuate the systemic toxicity and overcome the poor bioavailability, a very attractive approach is drug encapsulation in drug delivery nanosystems. The main focus of this review is to explore the actual cancer global problem, enunciate barriers to overcome in the pharmacological treatment of GBM, as well as the most updated drug delivery nanosystems for GBM treatment and how they influence biopharmaceutical properties of anti-GBM drugs. The discussion will approach lipid-based and polymeric nanosystems, as well as inorganic nanoparticles, regarding their technical aspects as well as biological effects in GBM treatment. Furthermore, the current state of the art, challenges to overcome and future perspectives in GBM treatment will be discussed.

show abstract

Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma

Cited by 42 publications

References 34 publications

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Magnetic Nanoparticles Used in Oncology

Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art

Contact Info

Product

Resources

About